Becton, Dickinson and Company (NYSE:BDX – Get Free Report) had its price objective hoisted by equities researchers at Citigroup from $208.00 to $241.00 in a research note issued to investors on Friday, Benzinga reports. The firm currently has a “buy” rating on the medical instruments supplier’s stock. Citigroup‘s target price indicates a potential upside of […]

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) had its price target boosted by investment analysts at Royal Bank Of Canada from $190.00 to $225.00 in a research note issued to investors on Friday, Benzinga reports. The firm presently has a “sector perform” rating on the medical instruments supplier’s stock. Royal Bank Of Canada‘s […]